Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors

2017 ◽  
Vol 20 (2) ◽  
pp. 140-149 ◽  
Author(s):  
F. Koinis ◽  
A. Voutsina ◽  
A. Kalikaki ◽  
A. Koutsopoulos ◽  
E. Lagoudaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Clinical Benefit ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tyrosine Kinase Inhibitors

scholarly journals Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

2008 ◽  
Vol 19 (9) ◽  
pp. 1605-1612 ◽  
Author(s):  
P.A. Zucali ◽  
M.G. Ruiz ◽  
E. Giovannetti ◽  
A. Destro ◽  
M. Varella-Garcia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tyrosine Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document